Actavia Life Sciences, Inc.
RASP
$0.004
-$0.0285-87.69%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 97.69% | 1.47% | 2.02% | 83.73% | -1,504.49% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -90.37% | -8.02% | -73.47% | -100.00% | 112.56% |
| Total Other Non-Cash Items | -99.79% | -25.93% | -59.71% | 106.73% | 849.88% |
| Change in Net Operating Assets | -57.21% | -36.16% | 134.80% | -25.72% | 11.42% |
| Cash from Operations | -50.42% | -3,278.57% | 103.52% | -51.46% | 65.00% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -68.00% | -- | -100.00% |
| Total Debt Repaid | 100.00% | 58.33% | 53.92% | 74.61% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 183.33% | -188.54% | -69.96% | 74.61% | -128.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.71% | -780.49% | 151.74% | 101.70% | -747.14% |
